Replies to post #1213021 on MOMO'S BREAKOUT BOARD

[HiddenGem69]

$NVLX Those results included an increase of about 4 months in median survival time over gemcitabine alone versus the 1.8 months seen with the ABRAXANE-gemcitabine combination. The results included a 100% increase in the one-year survival rate as compared to gemcitabine versus a 59% increase for the ABRAXANE-gemcitabine combination. The results obtained with Nuvilex's treatment are even more noteworthy given that only one-third of the dose of ifosfamide normally used to treat other types of cancer was used in the Phase II trials for advanced, inoperable pancreatic cancer.